Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUNCtion ALS trial of intrathecal TRCN-1023 in adults with ALS
NL-OMON61290Phase 2Recruiting
- Sponsor
- Trace Neuroscience
- Start
- Jun 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of TRCN-1023 in amyotrophic lateral sclerosis (ALS), sponsored by Trace Neuroscience. Primary endpoint: Frequency of adverse events. Started Jun 2026; status: recruiting.
02
Drugs
TRCN-1023
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON61290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61290.